Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.5
(2.6%)
USD 24.5
(2.6%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 623.64 Million USD | 507.94% |
| 2022 | 102.58 Million USD | -1.99% |
| 2021 | 104.66 Million USD | 55.59% |
| 2020 | 67.27 Million USD | 0.97% |
| 2019 | 66.62 Million USD | 32.68% |
| 2018 | 50.21 Million USD | 6.48% |
| 2017 | 47.15 Million USD | 25.01% |
| 2016 | 37.72 Million USD | -8.22% |
| 2015 | 41.09 Million USD | -5.95% |
| 2014 | 43.7 Million USD | 35.83% |
| 2013 | 32.17 Million USD | -15.34% |
| 2012 | 38 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 627.11 Million USD | 0.56% |
| 2024 Q2 | 620.58 Million USD | -1.04% |
| 2023 Q2 | 528.74 Million USD | 418.25% |
| 2023 Q4 | 623.64 Million USD | -7.27% |
| 2023 FY | 623.64 Million USD | 507.94% |
| 2023 Q1 | 102.02 Million USD | -0.54% |
| 2023 Q3 | 672.55 Million USD | 27.2% |
| 2022 Q4 | 102.58 Million USD | -0.64% |
| 2022 Q3 | 103.24 Million USD | -0.66% |
| 2022 FY | 102.58 Million USD | -1.99% |
| 2022 Q1 | 105.27 Million USD | 0.58% |
| 2022 Q2 | 103.92 Million USD | -1.28% |
| 2021 Q3 | 106.13 Million USD | 60.01% |
| 2021 Q2 | 66.32 Million USD | 2.56% |
| 2021 Q1 | 64.67 Million USD | -3.86% |
| 2021 FY | 104.66 Million USD | 55.59% |
| 2021 Q4 | 104.66 Million USD | -1.39% |
| 2020 Q2 | 64.7 Million USD | -2.81% |
| 2020 Q3 | 66.24 Million USD | 2.37% |
| 2020 Q4 | 67.27 Million USD | 1.55% |
| 2020 FY | 67.27 Million USD | 0.97% |
| 2020 Q1 | 66.57 Million USD | -0.07% |
| 2019 Q1 | 62.29 Million USD | 24.06% |
| 2019 FY | 66.62 Million USD | 32.68% |
| 2019 Q4 | 66.62 Million USD | 2.38% |
| 2019 Q3 | 65.07 Million USD | -3.19% |
| 2019 Q2 | 67.22 Million USD | 7.92% |
| 2018 Q1 | 45.76 Million USD | -2.95% |
| 2018 FY | 50.21 Million USD | 6.48% |
| 2018 Q4 | 50.21 Million USD | -1.92% |
| 2018 Q3 | 51.19 Million USD | -2.64% |
| 2018 Q2 | 52.58 Million USD | 14.9% |
| 2017 Q4 | 47.15 Million USD | -2.66% |
| 2017 FY | 47.15 Million USD | 25.01% |
| 2017 Q1 | 36.41 Million USD | -3.48% |
| 2017 Q2 | 46.31 Million USD | 27.19% |
| 2017 Q3 | 48.44 Million USD | 4.6% |
| 2016 Q1 | 40.26 Million USD | -2.02% |
| 2016 FY | 37.72 Million USD | -8.22% |
| 2016 Q4 | 37.72 Million USD | -11.67% |
| 2016 Q3 | 42.7 Million USD | 0.14% |
| 2016 Q2 | 42.64 Million USD | 5.9% |
| 2015 Q3 | 46.11 Million USD | -2.77% |
| 2015 Q2 | 47.43 Million USD | -2.04% |
| 2015 Q1 | 48.41 Million USD | 10.79% |
| 2015 FY | 41.09 Million USD | -5.95% |
| 2015 Q4 | 41.09 Million USD | -10.88% |
| 2014 Q4 | 43.7 Million USD | -14.9% |
| 2014 Q3 | 51.34 Million USD | -4.05% |
| 2014 Q2 | 53.51 Million USD | 28.95% |
| 2014 Q1 | 41.5 Million USD | 28.99% |
| 2014 FY | 43.7 Million USD | 35.83% |
| 2013 Q3 | 33.26 Million USD | 0.0% |
| 2013 Q4 | 32.17 Million USD | -3.28% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 32.17 Million USD | -15.34% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | 38 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | -97.776% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -531.076% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 7.51% |
| Cosmos Health Inc. | 12.42 Million USD | -4919.675% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -60265.206% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -15.287% |
| Cronos Group Inc. | 2.53 Million USD | -24453.434% |
| Incannex Healthcare Limited | 373 Thousand USD | -167096.247% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1616.934% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -378.4% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -1042657.537% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -94720.93% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -94720.93% |
| SCYNEXIS, Inc. | 15.08 Million USD | -4035.557% |
| Safety Shot Inc | 1.54 Million USD | -40161.618% |
| Theratechnologies Inc. | 58.96 Million USD | -957.594% |
| Alpha Teknova, Inc. | 30.45 Million USD | -1947.547% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -11275.23% |
| Pacira BioSciences, Inc. | 586.04 Million USD | -6.416% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -102472.697% |
| Dynavax Technologies Corporation | 256.91 Million USD | -142.743% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 12.843% |
| Radius Health, Inc. | 365.31 Million USD | -70.714% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -23456.283% |
| Alvotech | 1.07 Billion USD | 42.012% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -3581.91% |
| SIGA Technologies, Inc. | 1.46 Million USD | -42498.235% |
| Shineco, Inc. | 29.65 Million USD | -2002.889% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Journey Medical Corporation | 17.73 Million USD | -3417.439% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -7435.01% |
| Embecta Corp. | 1.63 Billion USD | 61.938% |
| Harrow Health, Inc. | 190.5 Million USD | -227.368% |
| Procaps Group, S.A. | 285.93 Million USD | -118.106% |
| Biofrontera Inc. | 5.39 Million USD | -11451.065% |
| DURECT Corporation | 20.74 Million USD | -2906.083% |
| PainReform Ltd. | 86 Thousand USD | -725065.116% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1401.775% |
| OptiNose, Inc. | 131.74 Million USD | -373.356% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -53066.139% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -422.528% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -3284.12% |
| ProPhase Labs, Inc. | 21.38 Million USD | -2816.941% |
| Phibro Animal Health Corporation | 525.45 Million USD | -18.685% |
| Procaps Group S.A. | 285.93 Million USD | -118.106% |
| TherapeuticsMD, Inc. | 8 Million USD | -7690.656% |
| Viatris Inc. | 18.12 Billion USD | 96.559% |
| Rockwell Medical, Inc. | 13.43 Million USD | -4540.539% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -4022.163% |
| Tilray Brands, Inc. | 387.31 Million USD | -61.016% |
| PetIQ, Inc. | 468.3 Million USD | -33.171% |
| Talphera, Inc. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -45.575% |
| Alimera Sciences, Inc. | 67.39 Million USD | -825.299% |
| Assertio Holdings, Inc. | 40.91 Million USD | -1424.35% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -57236.163% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -1662.497% |
| Hempacco Co., Inc. | 13.72 Million USD | -4444.004% |
| Alvotech | 1.07 Billion USD | 42.012% |
| Lantheus Holdings, Inc. | 616.94 Million USD | -1.085% |
| Kamada Ltd. | 8.74 Million USD | -7028.162% |
| Currenc Group, Inc. | 31.94 Million USD | -1852.32% |
| Indivior PLC | 281.6 Million USD | -121.462% |
| Evoke Pharma, Inc. | 5 Million USD | -12372.84% |
| Flora Growth Corp. | 3.67 Million USD | -16883.715% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -60265.206% |
| Evolus, Inc. | 126.54 Million USD | -392.818% |
| HUTCHMED (China) Limited | 86.13 Million USD | -624.062% |
| Akanda Corp. | 3.99 Million USD | -15495.764% |